BERGEN, Norway, October 5, 2018 /PRNewswire/ --
BerGenBio ASA (OSE: BGBIO) announces that the first patient has been dosed in the second stage of the phase II
Growth Capitalist (https://growthcapitalist.com/2018/10/bergenbio-enters-second-stage-of-phase-ii-trial-with-selective-axl-inhibitor-bemcentinib-in-combination-with-keytruda-in-patients-with-advanced-nsclc/)
BERGEN, Norway, October 5, 2018 /PRNewswire/ --
BerGenBio ASA (OSE: BGBIO) announces that the first patient has been dosed in the second stage of the phase II